Engagement at Upcoming Investor Relations Events
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a biotechnology company focusing on precision medicine in oncology, has announced its intention to participate in several upcoming investor relations events. These engagements signify the company's dedication to advancing cancer therapeutics and engaging with investors interested in innovative healthcare solutions.
Citi's 2026 Virtual Oncology Leadership Summit
One of the highlighted events will be Citi's Virtual Oncology Leadership Summit taking place on February 18, 2026, at 1:00 PM ET. During this event, a pivotal fireside chat will be held featuring prominent leaders from IDEAYA:
Insightful Discussions
Darrin Beaupre, the Chief Medical Officer, Michael White, the Chief Scientific Officer, and Joshua Bleharski, the Chief Financial Officer, will participate in a session hosted by Yigal D. Nochomovitz, Ph.D., the Director and SMid Cap Biotech Analyst. This interactive discussion aims to shed light on IDEAYA's innovative approaches and breakthroughs in targeted therapies for cancer.
IDEAYA's Virtual Fireside Chat
Another significant event is IDEAYA's Virtual Fireside Chat scheduled for February 23, 2026, at 12:00 PM ET. This session will be hosted by Umer Raffat of Evercore ISI, providing an additional platform for in-depth dialogue.
Expert Panel Discussions
Participants will include Yujiro S. Hata, the President and Chief Executive Officer, alongside Darrin Beaupre and Michael White, further emphasizing the strategic direction and clinical advancements IDEAYA is pursuing. This engaging chat is designed to elevate investor awareness about the company's transformative research and its impact on cancer treatment.
Webcast Availability
Both events will be available via live audio webcast under the Investors/Events section on the IDEAYA website. Following the events, replays will be accessible for 30 days, allowing investors who missed the live sessions to catch up on valuable content and insights shared by the team.
About IDEAYA Biosciences
Founded on a commitment to precision medicine, IDEAYA Biosciences strives to discover and develop transformative cancer therapies. The company merges extensive expertise in small-molecule drug discovery, structural biology, and bioinformatics. IDEAYA leverages these capabilities to identify and validate translational biomarkers for targeted therapies, ultimately leading to groundbreaking advancements.
IDEAYA has developed a robust pipeline emphasizing synthetic lethality and antibody-drug conjugates (ADCs). These are intended for molecularly defined solid tumor indications. The mission of IDEAYA is to deliver the next generation of precision oncology therapies that are more personalized and effective, aiming to enhance clinical outcomes for cancer patients globally.
Frequently Asked Questions
What is the focus of IDEAYA Biosciences?
IDEAYA Biosciences specializes in precision medicine for oncology, focusing on discovering targeted therapeutics for cancer treatments.
When will the upcoming investor events take place?
The upcoming investor events will occur on February 18 and February 23, 2026.
Who will be involved in the discussions during the events?
Key leaders from IDEAYA, including the Chief Medical Officer, Chief Scientific Officer, and Chief Executive Officer, will participate in the discussions.
How can investors access the event discussions?
Investors can access live webcasts of the discussions through the IDEAYA website's Investors/Events section, with replays available for 30 days afterward.
What is IDEAYA's mission?
IDEAYA aims to provide innovative and effective cancer therapies that are tailored to the unique genetic makeup of diseases.